secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037180
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q3 total revenue $34M (+79% YoY); FDA PDUFA date March 31, 2024
------------------------------------------------------------------------

- Q3 total revenue $34.0M (+79% YoY); U.S. product revenue $20.3M (+45% YoY).
- Net loss $41.3M ($0.37 per share) vs $55.1M ($0.81) in prior year.
- FDA accepted sNDA for expanded CV risk reduction label; PDUFA date March 31, 2024.
- Cash $114.8M at Sep 30 vs $166.9M at Dec 31; FY 2023 OpEx guidance $225-245M.
- Presented CLEAR Outcomes analyses at ESC showing 20% reduction in total MACE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/0001628280-23-037180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/espr-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer